US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
DE102004029784A1
(de)
*
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004033670A1
(de)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060074088A1
(en)
*
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
US7728134B2
(en)
*
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
EP1630163A1
(de)
*
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
EP1632493A1
(de)
|
2004-08-25 |
2006-03-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
JP2008510771A
(ja)
|
2004-08-27 |
2008-04-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
|
WO2006044687A2
(en)
|
2004-10-15 |
2006-04-27 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
DE102004058337A1
(de)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
PL1948180T3
(pl)
|
2005-11-11 |
2013-09-30 |
Boehringer Ingelheim Int |
Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
|
US7439358B2
(en)
*
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
AU2012256410B2
(en)
*
|
2006-02-08 |
2016-04-28 |
Boehringer Ingelheim International Gmbh |
Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation
|
US7622463B2
(en)
|
2006-02-14 |
2009-11-24 |
Vertex Pharmaceuticals Incorporated |
Dihydrodiazepines useful as inhibitors of protein kinases
|
CN101448830A
(zh)
*
|
2006-05-19 |
2009-06-03 |
阿斯利康(瑞典)有限公司 |
作为抗增殖剂的二氢碟啶化合物
|
TW200808325A
(en)
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
GEP20135728B
(en)
|
2006-10-09 |
2013-01-25 |
Takeda Pharmaceuticals Co |
Kinase inhibitors
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
ES2627352T3
(es)
|
2006-10-19 |
2017-07-27 |
Signal Pharmaceuticals, Llc |
Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
|
AU2007334379B2
(en)
|
2006-12-14 |
2013-04-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as protein kinase inhibitors
|
AU2007338754A1
(en)
|
2006-12-21 |
2008-07-03 |
Vertex Pharmaceuticals Incorporated |
5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
EP1953163A1
(en)
*
|
2007-02-01 |
2008-08-06 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pteridinone derivatives as PI3-kinases inhibitors
|
US8329695B2
(en)
|
2007-08-03 |
2012-12-11 |
Boehringer Ingelheim International Gmbh |
Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
|
EP2610256B1
(en)
|
2007-09-28 |
2016-04-27 |
Cyclacel Limited |
Pyrimidine derivatives as protein kinase inhibitors
|
WO2009067547A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
JP5400791B2
(ja)
*
|
2007-12-04 |
2014-01-29 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
置換ジヒドロプテリジン−6−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
GB0807452D0
(en)
*
|
2008-04-24 |
2008-05-28 |
Chroma Therapeutics Ltd |
PLK inhibitors
|
CA2728830A1
(en)
*
|
2008-06-23 |
2010-01-21 |
Jean-Damien Charrier |
Protein kinase inhibitors
|
DK2331092T3
(da)
|
2008-08-21 |
2014-05-19 |
Univ Johns Hopkins |
Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer
|
US20100075973A1
(en)
*
|
2008-08-28 |
2010-03-25 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
CN102272134B
(zh)
|
2008-12-09 |
2013-10-16 |
吉里德科学公司 |
Toll样受体调节剂
|
EP3828185A3
(en)
*
|
2009-01-06 |
2021-09-01 |
Dana Farber Cancer Institute, Inc. |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
RS57869B1
(sr)
|
2009-06-17 |
2018-12-31 |
Vertex Pharma |
Inhibitori replikacije virusa gripa
|
US8476270B2
(en)
|
2009-09-14 |
2013-07-02 |
Gilead Sciences, Inc. |
Dihydropyrido[4,3-b]pyrazine-3-ones as modulators of toll-like receptors
|
CN102020643A
(zh)
|
2009-09-22 |
2011-04-20 |
上海恒瑞医药有限公司 |
二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
|
AU2010299579A1
(en)
|
2009-09-25 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
RU2012116526A
(ru)
|
2009-09-25 |
2013-10-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
|
BR112012009751A2
(pt)
|
2009-10-26 |
2020-09-24 |
Signal Pharmaceuticals, Llc |
métodos de síntese e purificação de heteroarila
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
US8541418B2
(en)
*
|
2009-12-23 |
2013-09-24 |
Elan Pharmaceutical, Inc. |
Inhibitors of polo-like kinase
|
WO2011101369A1
(en)
|
2010-02-17 |
2011-08-25 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones, method for production and use thereof
|
CN102190669A
(zh)
*
|
2010-03-19 |
2011-09-21 |
江苏恒瑞医药股份有限公司 |
二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
|
WO2012027495A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of The Pacific |
Piperazinylpyrimidine analogues as protein kinase inhibitors
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
RU2013132681A
(ru)
|
2010-12-16 |
2015-01-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы репликации вирусов гриппа
|
US20130131069A1
(en)
|
2011-05-13 |
2013-05-23 |
Boehringer Ingelheim International Gmbh |
Method for treatment of solid malignancies including advanced or metastatic solid malignancies
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
TWI758746B
(zh)
|
2011-10-19 |
2022-03-21 |
美商標誌製藥公司 |
以tor激酶抑制劑治療癌症
|
JP2015501793A
(ja)
|
2011-11-10 |
2015-01-19 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
ジヒドロプテリジノン類
|
MY169749A
(en)
|
2011-12-02 |
2019-05-15 |
Signal Pharm Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
JP5807750B2
(ja)
*
|
2012-01-05 |
2015-11-10 |
トヨタ自動車株式会社 |
締付装置及び締付方法
|
US9006226B2
(en)
|
2012-02-23 |
2015-04-14 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones I
|
US8865716B2
(en)
|
2012-02-23 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones II
|
ES2742398T3
(es)
|
2012-02-24 |
2020-02-14 |
Signal Pharm Llc |
Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
US20140154304A1
(en)
|
2012-11-30 |
2014-06-05 |
Boehringer Ingelheim International Gmbh |
Combination therapy with volasertib
|
TW201441227A
(zh)
|
2013-01-16 |
2014-11-01 |
Signal Pharm Llc |
經取代吡咯并嘧啶化合物、其組合物及其治療方法
|
EP2958919B1
(en)
*
|
2013-02-21 |
2019-05-22 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones i
|
EP2958918B1
(en)
|
2013-02-21 |
2016-12-07 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones ii
|
US9358232B2
(en)
|
2013-04-17 |
2016-06-07 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
WO2014172425A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
EP2986298A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Treatment of cancer with dihydropyrazino-pyrazines
|
SG11201508527VA
(en)
|
2013-04-17 |
2015-11-27 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
CA2909625C
(en)
|
2013-04-17 |
2021-06-01 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
BR112015026257B1
(pt)
|
2013-04-17 |
2022-12-20 |
Signal Pharmaceuticals, Llc |
Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
|
BR112015026247B1
(pt)
|
2013-04-17 |
2022-08-23 |
Signal Pharmaceuticals, Llc |
Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
|
CN113831345A
(zh)
|
2013-05-29 |
2021-12-24 |
西格诺药品有限公司 |
二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
|
US20150031699A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
ES2741444T3
(es)
|
2013-11-13 |
2020-02-11 |
Vertex Pharma |
Inhibidores de la replicación de virus de la gripe
|
RS57541B1
(sr)
|
2013-11-13 |
2018-10-31 |
Vertex Pharma |
Postupci za pripremu inhibitora replikacije virusa gripa
|
US20160347750A1
(en)
*
|
2014-01-31 |
2016-12-01 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
EP3099693A4
(en)
|
2014-01-31 |
2017-08-16 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
US9718824B2
(en)
|
2014-04-16 |
2017-08-01 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
|
WO2015160880A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
EP3131552B1
(en)
|
2014-04-16 |
2020-07-15 |
Signal Pharmaceuticals, LLC |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
CN104003989B
(zh)
*
|
2014-05-26 |
2015-11-11 |
苏州明锐医药科技有限公司 |
伏拉塞替及其中间体的制备方法
|
MX2017000026A
(es)
|
2014-07-11 |
2017-05-01 |
Gilead Sciences Inc |
Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
EA201790189A1
(ru)
|
2014-07-14 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
|
BR112017002369A2
(pt)
|
2014-08-08 |
2017-12-05 |
Dana Farber Cancer Inst Inc |
derivados de diazepana e usos dos mesmos
|
MX2017001757A
(es)
*
|
2014-08-08 |
2017-05-30 |
Dana Farber Cancer Inst Inc |
Derivados de dihidropteridinona y sus usos.
|
MX2017003284A
(es)
|
2014-09-16 |
2017-06-28 |
Gilead Sciences Inc |
Formas solidas de modulador de receptor tipo toll.
|
EP3848375B1
(en)
|
2014-09-16 |
2023-12-27 |
Gilead Sciences, Inc. |
Methods of preparing intermediates for toll-like receptor modulators
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
JP6704416B2
(ja)
|
2015-05-13 |
2020-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
インフルエンザウイルスの複製の阻害剤を調製する方法
|
EP3294735B8
(en)
|
2015-05-13 |
2022-01-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
BR112018004618A2
(pt)
|
2015-09-11 |
2018-09-25 |
Dana-Farber Cancer Institute, Inc. |
ciano tienotriazoldiazepinas e usos das mesmas
|
CN108472299A
(zh)
|
2015-09-11 |
2018-08-31 |
达纳-法伯癌症研究所股份有限公司 |
乙酰胺噻吩并三唑并二氮杂环庚三烯及其用途
|
EP3370712A4
(en)
|
2015-11-06 |
2019-10-09 |
The Johns Hopkins University |
METHODS OF TREATING HEPATIC FIBROSIS BY ADMINISTERING 3-BROMOPYRUVATE
|
MX2018006499A
(es)
|
2015-11-25 |
2018-08-01 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos.
|
CN105801582A
(zh)
*
|
2016-04-12 |
2016-07-27 |
合肥工业大学 |
一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途
|
DE102017005089A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
|
DE102017005091A1
(de)
|
2016-05-30 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
|
CN106977584B
(zh)
*
|
2017-04-19 |
2019-12-06 |
吉林大学 |
靶向泛素化降解plk1和brd4蛋白的化合物及其应用
|
AU2018289539B2
(en)
|
2017-06-22 |
2024-07-04 |
Celgene Corporation |
Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
|
EP3728268A4
(en)
*
|
2017-12-22 |
2021-07-28 |
Dana-Farber Cancer Institute, Inc. |
NEK INHIBITORS AND METHODS OF USE
|
US20210038602A1
(en)
|
2018-01-25 |
2021-02-11 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia
|
WO2020113094A1
(en)
|
2018-11-30 |
2020-06-04 |
Nuvation Bio Inc. |
Pyrrole and pyrazole compounds and methods of use thereof
|
CN110343109B
(zh)
*
|
2019-08-21 |
2021-11-23 |
郑州大学 |
一种二氢蝶啶酮-磺酰胺类衍生物及其药学上可接受的盐、其制备方法及其应用
|
TW202404636A
(zh)
|
2022-04-08 |
2024-02-01 |
美商英伊布里克斯公司 |
Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法
|